<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047966</url>
  </required_header>
  <id_info>
    <org_study_id>UGranada</org_study_id>
    <nct_id>NCT04047966</nct_id>
  </id_info>
  <brief_title>Study of the Fetal and Maternal Microbiota in Preganant Women With Fetal Defect Growth</brief_title>
  <acronym>BIOCIR</acronym>
  <official_title>Study of the Fetal and Maternal Microbiota in Preganant Women With Fetal Defect Growth Nad Its Relationship With Inflammatory Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Granada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an observational and prospective study that will include consecutively 63 controls
      (fetuses with estimated fetal weight above the 10th centile) and 63 fetuses with defects in
      fetal growth (estimated fetal weight below the 10th percentile) during the third trimester
      (32-26 weeks) with gestational age at birth equal or over 37 weeks. Investigators will
      collect: (1) Obstetric and nutritional questionnaires, (2) maternal samples between 32-36
      weeks (feces), (3) intrapartum samples (maternal blood, cord blood and placenta) and (4)
      postpartum samples (meconic and newborn feces at 6 weeks of life)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an observational and prospective study to determine the influence of the
      gastrointestinal microbiome on the intrauterine growth restriction (IUGR). For this purpose,
      investigators are planning to recruit 63 women with a diagnoses of IUGR and 63 pregnant women
      with a normal intrauterine growth.

      Samples will be taken during third trimester (fecal and blood maternal sample), intrapartum
      (maternal blood, umbilical cord blood and placenta tissue sample) and post partum samples
      (meconic and newborn fecal samples at 6 weeks of life).

      Also, obstetric and nutritional information will be registered by means of specific
      questionnaires.

      Fecal samples will be use to study the gastrointestinal microbiome by Next Generation
      Sequencing techniques, whereas inflammatory biomarkers will be determine in plasma samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal microbiome composition (16S RNA amplicon sequencing)</measure>
    <time_frame>From May to July 2020</time_frame>
    <description>To determine the main gastrointestinal microbiota composition, by 16S RNA amplicon sequencing, in fecal samples of pregnant women and their newborn (meconic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of inflammatoy biomarkers</measure>
    <time_frame>From May to July 2020</time_frame>
    <description>To determine plasma inflammatory biomarkers levels (LPS, LBP, IL6, 8, 10, 13,15 IFN-gamma, VEGF) in pregnant woman by inmunoassay determination</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Fetal growth restriction</arm_group_label>
    <description>63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>63 control fetuses with an estimated fetal weight about the 10th percentile</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will recruit fecal samples to obtain bacterial DNA for metagenomics analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        63 controls (fetuses with estimated fetal weight above the 10th centile) and 63 fetuses
        with defects in fetal growth (estimated fetal weight below the 10th percentile) during the
        third trimester (32-26 weeks) with gestational age at birth equal or over 37 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intrauterine Growth restriction (32-36 weeks)

          -  Vaginal delivery

          -  Delivery at 37 weeks

        Exclusion Criteria:

          -  Alcohol, tabacco or other drugs consumption during pregnancy

          -  Antibiotic use before recruitment (3 months) or during pregnancy until delivery

          -  Gestational diabetes

          -  Fetuses anormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Gomez Llorente, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Granada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina Gomez Llorente, PhD</last_name>
    <phone>+34958241000</phone>
    <phone_ext>40092</phone_ext>
    <email>gomezll@ugr.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergi Fernandez Gonzalez, MD</last_name>
    <phone>+34647032559</phone>
    <email>sfernandezgo@hsjdbcn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics and Gynecology, Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergi Fernandez-Gonzalez, MD</last_name>
      <phone>+34647032559</phone>
      <email>sfernandezgo@hsjdbcn.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Granada</investigator_affiliation>
    <investigator_full_name>Carolina Gómez Llorente</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intrauterine Growth restriction</keyword>
  <keyword>Gastrointestinal microbiome</keyword>
  <keyword>Inflammatory biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

